MOSCOW, March 1. / TASS /. The Federal Biomedical Agency (FMBA) of Russia plans to complete the first phase of clinical trials of the Mir-19 direct-acting coronavirus drug by mid-March. This was announced on Monday by the head of the department Veronika Skvortsova.
“On December 30, we received permission for clinical trials – everything was already completed, the entire preclinic. Immediately after the New Year, these clinical trials began. But taking into account the fact that this is a new molecule – it is new and patented and has no analogues – we are the first phase we go through especially carefully, because we need to prove the safety of people. We will finish the first phase by mid-March and move on to working with patients, we are moving on to the second phase, ” – said Skvortsova.
Skvortsova explained that the drug is based on the use of microRNAs that block certain sites of the RNA virus. It was named Mir-19. “Because microRNA, first of all, is absolutely safe for humans, it does not affect the human genome, it does not affect human immunity, but at the same time it highly efficiently infects the virus (in experiments on animals, the carriage of viruses decreases 10 thousand times), but, in addition, it prevents the most severe forms of coronavirus infection, including preventing pneumonitis, acute respiratory distress syndromes against the background of coronavirus infection, ”said the head of the FMBA.
Skvortsova said that clinical trials of a coronavirus vaccine (on humans) developed by FMBA will begin in July.